Idiopathic multicentric Castleman disease presenting as generalized lymphadenopathy: A case report
DOI:
https://doi.org/10.15305/ijrci/v14i1/357Keywords:
Idiopathic multicentric Castleman disease ,, lymphadenopathy,, HHV-8, HIVAbstract
A 48-year-old male presented with easy fatigability, and on evaluation, he was found to have generalized lymphadenopathy and elevated erythrocyte sedimentation rate (ESR-70 mm/hr). Neck ultrasound revealed enlarged left paratracheal lymph nodes. He had positive Mantoux test, a diagnosis of tuberculous lymphadenopathy was made and started on antitubercular medication. However, the patient’s condition deteriorated over the next month with new onset of dyspnea on exertion, dysphagia, generalized pruritus, and progressive persistent lymphadenopathy. Laboratory results indicated elevated ESR (72 mm/hr), gamma-glutamyl transpeptidase (GGTP 370 U/L), and AST (95 U/L) levels, although alkaline phosphatase levels were normal. The hemogram and liver, renal, and thyroid function test results were normal. CRP, autoantibody tests, and Serum Protein Electrophoresis results were also negative. CT thorax revealed cervical, Axillary, Hilar and Mediastinal Lymphadenopathy. The left axillary lymph node biopsy was negative for tuberculosis (AFB and PCR) but exhibited histological characteristics indicative of Castleman disease. His viral serology was negative for VDRL, HIV, HBSAG, and HCV. Immunohistochemistry (IHC) on lymph node biopsy was negative for the lymphoma panel and HHV 8. The diagnosis of idiopathic multicentric Castleman disease (iMCD) was confirmed using clinical, laboratory, and histological evaluations after the elimination of viral and neoplastic etiologies. He was initially treated with intravenous steroids, followed by oral steroids and immunosuppressive drugs.
References
1. Lang E, van Rhee F. Idiopathic multicentric Castleman disease: an update in diagnosis and treatment advances. Blood Rev. 2024;64:101161.
2. Nijim S, Fajgenbaum DC. Identifying Castleman disease from non-clonal inflammatory causes of generalized lymphadenopathy. Hematology Am Soc Hematol Educ Program. 2024;2024(1):582-593.
3. Sebastian N, Nawaz SPN, Ananthkrishnan R, Kumanan J, Lakshmanan A, Rajan T. Idiopathic multicentric Castleman disease: a mysterious case of generalized lymphadenopathy. Int J Res Med Sci. 2023;11:3087-3091.
4. González García A, Fernández-Martín J, Robles Marhuenda Á. Idiopathic multicentric Castleman disease and associated autoimmune and autoinflammatory conditions: practical guidance for diagnosis. Rheumatology (Oxford). 2023;62(4):1426-1435.
5. Hoffmann C, Oksenhendler E, Littler S, Grant L, Kanhai K, Fajgenbaum DC. The clinical picture of Castleman disease: a systematic review and meta-analysis. Blood Adv. 2024;8(18):4924-4935.
6. Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, Wu D, Srkalovic G, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood. 2017;129(12):1646-1657.
7. Blommers M, Selegean S, Wood RK, Sarmiento Bustamante M, Shyamsundar S, Wiley EA, et al. Idiopathic multicentric Castleman disease with marrow fibrosis and extramedullary hematopoiesis. Eur J Haematol. 2024;113(6):833-841.
8. Sawada E, Shioda Y, Ogawa K, Iwashita T, Ono Y, Hasegawa H, et al. A case of Castleman's disease with a marked infiltration of IgG4-positive cells in the renal interstitium. Diagnostics (Basel). 2024;14(5):476.
9. Strach M, Kuszmiersz P, Chmura Ł, Korkosz M. A challenging diagnosis of idiopathic multicentric Castleman disease with complex systemic presentation: a case report. Clin Case Rep. 2023;11(10):e7981.
10. Schmalzing M, Sander O, Seidl M, Marks R, Blank N, Kötter I, et al. Castleman's disease in the rheumatological practice. Z Rheumatol. 2024;83(Suppl 3):289-298.